McDermott +Bull has successfully placed Enrico Brambilla as Vice President, Product Research and Development at Eyenovia. Reporting to the COO, Enrico will lead a team of high-performing engineers and be accountable for the design, development, and qualification of drug-device research; pre- and post-FDA approval activities; and total lifecycle management of Eyenovia product offerings.

Enrico has over 15 years of experience in med-device, including a recent ophthalmology innovation for glaucoma treatment. He’s experienced in IP creation, patent submissions, regulatory requirements, clinical trials, and FDA documentation. He has an impressive 50 patents granted, published, or submitted internationally.

Eyenovia is a clinical-stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology. 

This executive search was completed by McDermott + Bull Partner Jake Vander Zanden, Executive Recruiter Andrea Richter, Senior Research Associate Josh Nichols, and Research Associate Michael Matranga.